Objective To investigate the effect and safety of recombinant human endostatin combined with FOLFIRI in the elderly patients with colon cancer. Methods According to random number table method, 100 elderly patients with colon cancer from March 2012 to March 2015 in our hospital were selected and divided into control group ( patients receiving FOLFIRI chemotherapy) and experimental group ( patients receiving recombinant human endostatin combined with FOLFIRI regimen).The efficacy and the adverse reactions were analyzed and compared between two groups. Results The total remission rate in experimental group was significantly higher than that in control group ( P<0�05) . The incidence rate of adverse reactions showed no significant differences between two groups ( P>0�05 ) . Conclusions Compared with simple FOLFIRI regimen, recombinant human endostatin combined with FOLFIRI regimen in the treatment could significantly improve patients� outcome and prolong the survival time of the elderly patients with colon cancer, with less adverse reactions.%目的：为了进一步提高老年结肠癌患者的治疗效果并减少各种不良反应的发生率，本研究探讨重组人血管内皮抑素联合FOLFIRI方案治疗的价值和意义。方法选取100例于2012年3月至2015年3月在我院治疗的老年结肠癌患者作为研究对象并按照双盲对照的原则采用随机数字表的方法分为试验组和对照组，每组各50例，对照组患者采取FOLFIRI方案化疗，而试验组患者采取重组人血管内皮抑素联合FOLFIRI方案治疗，比较2种治疗方案的疗效以及不良反应的发生率。结果试验组和对照组均获得较好疗效，但是试验组患者总缓解率更高，2组比较差异具有统计学意义（ P＜0�05）。2组均有不同程度的不良反应发生，但差异无统计学意义（ P＞0�05）。结论重组人血管内皮抑素联合FOLFIRI方案治疗，能够明显提高老年结肠癌患者的治疗效果，延长其生存期，且不增加不良反应，值得推荐。
展开▼
